Nuvi lex, Inc., Johnson & Johnson, and Medtronic, Inc. , All Designing Type of Artificial Pancreas for Diabetics
While Medtronic, Inc. (NYSE: M D T) and Johnson & Johnson (NYSE: JNJ) are developing devices that can fundamentally act as a type of “artificial pancreas,” N_u_v_i_l_e_x, Inc. (OTCQB: N-V-L-X) unique cell encapsulation technology has indicated it too can invent a type of “artificial pancreas” in preclinical diabetes studies. Their advances couldn’t be more unalike; however, all three organizations are sure that inventing an artificial pancreas gives diabetics the greates solution to independently track their blo_od sugar levels, and in turn, offer them with insulin as desired.
As the two N_Y_S_E|N-Y-S-E|NYSE}-traded companies seek out medical devices represent their brand of artificial pancreas, the small, Silver Spring, Maryland-located biotech, Nuvilex, is turning to a much more minor and different possibility – transplanted living, insulin-producing cells enclosed in capsules just about the size of the head of a pin, that form a bundle and act as a miniature cell factory that makes insulin upon demand within the diabetics physique.
The use of research materials issued by the auth.or is done at your own risk. You are encouraged to do your own research before making any investment decision in regards to the secu rity discussed herein. The author has not been rewarded by any entity in connection with the distribution of these materials. You should assume that as of the date of this report or letter, the author, possibly along with or through our owners, affiliates, employees and/or consultants, (communally referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the disbursement of any report or letter, the author plans to continue engaging in trnsactns in the secu rity covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice. This practice could end in our trading securities at any time before, during, and/or after the distribution of this report.
